Literature DB >> 26472500

Increased red cell distribution width is associated with poor stem cell mobilization in patients with advanced chronic heart failure.

Gregor Poglajen1, Matjaž Sever2, Peter Černelč2, Francois Haddad3, Bojan Vrtovec1.   

Abstract

Parameters associated with poor CD34(+) stem cell mobilization in advanced chronic heart failure (CHF) patients were investigated. Forty-four CHF patients underwent bone marrow stimulation with granulocyte colony stimulating factor. Poor cell mobilization presents in 32% of patients. Poor and good mobilizers did not differ significantly regarding age, gender, left ventricular ejection fraction, kidney or liver function and exercise capacity. Significant differences were found regarding NT-proBNP levels and red cell distribution width (RDW). Increased RDW was the only independent predictor of poor CD34(+) stem cell mobilization on multivariable analysis and may serve as a biomarker of poor stem cell mobilization in CHF patients.

Entities:  

Keywords:  Bone marrow; heart failure; stem cell therapy

Mesh:

Substances:

Year:  2015        PMID: 26472500     DOI: 10.3109/1354750X.2015.1094137

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  3 in total

1.  Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, Mean Platelet Volume and Red Cell Distribution Width Measures in Bells Palsy.

Authors:  Caner Sahin; Ceyhun Varım
Journal:  Open Access Maced J Med Sci       Date:  2017-01-09

2.  Red cell distribution width as a predictor of multiple organ dysfunction syndrome in patients undergoing heart valve surgery.

Authors:  Piotr Duchnowski; Tomasz Hryniewiecki; Mariusz Kuśmierczyk; Piotr Szymanski
Journal:  Biol Open       Date:  2018-10-16       Impact factor: 2.422

Review 3.  Red Blood Cell Distribution Width in Heart Failure: Pathophysiology, Prognostic Role, Controversies and Dilemmas.

Authors:  Andrew Xanthopoulos; Grigorios Giamouzis; Apostolos Dimos; Evangelia Skoularigki; Randall C Starling; John Skoularigis; Filippos Triposkiadis
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.